Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 …
LN Cosenso-Martin, LT Giollo-Júnior… - Diabetology & Metabolic …, 2015 - Springer
Background Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2 diabetes
mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to …
mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to …
Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial
LN Cosenso-Martin, LT Giollo-Júnior, LAB Fernandes… - Acta …, 2018 - Springer
Aims Several trials have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors, used to treat
type 2 diabetes (T2DM), improve endothelial function. The current study investigated the …
type 2 diabetes (T2DM), improve endothelial function. The current study investigated the …
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin …
N Kitao, H Miyoshi, T Furumoto, K Ono… - Cardiovascular …, 2017 - Springer
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects
in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects …
in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects …
Randomized study comparing vildagliptin vs glibenclamide on glucose variability and endothelial function in patients with type 2 diabetes mellitus and hypertension
LN Cosenso-Martin, LY Takaoka… - … Syndrome and Obesity, 2020 - Taylor & Francis
Background Glucose variability (GV) is considered an important factor for cardiovascular
disease (CVD) in patients with type 2 diabetes mellitus (T2DM). High GV causes endothelial …
disease (CVD) in patients with type 2 diabetes mellitus (T2DM). High GV causes endothelial …
The role of vildagliptin in treating hypertension through modulating serum VEGF in diabetic hypertensive patients
AR El-Naggar, D Zaafar, M Elyamany… - Journal of …, 2019 - journals.sagepub.com
Background: Several trials have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors are
used to improve endothelial function in addition to treating type 2 diabetes (T2DM). The …
used to improve endothelial function in addition to treating type 2 diabetes (T2DM). The …
Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on the Parameters of Glucose Metabolism and the Cardio-Ankle Vascular Index in Individuals with Type 2 …
D Nagayama, H Kawana, Y Watanabe… - Journal of Clinical …, 2024 - mdpi.com
DPP-4 inhibitors are frequently used as first-line agents for the treatment of type 2 diabetes
in Japan. This study aimed to examine the effects of vildagliptin on glucose metabolism and …
in Japan. This study aimed to examine the effects of vildagliptin on glucose metabolism and …
The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus
G Kim, S Oh, SM Jin, KY Hur, JH Kim… - Expert Opinion on …, 2017 - Taylor & Francis
Objective: To compare the effects of either vildagliptin or glimepiride on glycemic variability,
oxidative stress, and endothelial parameters in patients with type 2 diabetes mellitus (T2DM) …
oxidative stress, and endothelial parameters in patients with type 2 diabetes mellitus (T2DM) …
Vildagliptin significantly decreases blood pressure (BP) in hypertensive patients (pts) with type 2 diabetes (T2DM) compared with metformin.
Vildagliptin is a potent and selective DPP-4 inhibitor that improves glycemic control in pts
with T2DM by increasing α-and β-cell responsiveness to glucose. It was previously noted …
with T2DM by increasing α-and β-cell responsiveness to glucose. It was previously noted …
Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus
I Zografou, C Sampanis, E Gkaliagkousi, F Iliadis… - Hormones, 2015 - Springer
OBJECTIVE: To evaluate the effect of dipeptidyl-peptidase-4 (DPP-4) inhibitor vildagliptin on
high sensitivity C-reactive protein (hsCRP) and arterial stiffness (AS) in patients with type 2 …
high sensitivity C-reactive protein (hsCRP) and arterial stiffness (AS) in patients with type 2 …
30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-naïve women with diabetes and …
A Schiapaccassa, PA Maranhão… - Diabetology & Metabolic …, 2019 - Springer
Background Obesity is the main risk factor for diabetes and excessive visceral fat triggers
low-grade inflammatory process, mediated by activation and release of cytokines and high …
low-grade inflammatory process, mediated by activation and release of cytokines and high …